Extracellular vesicles produced by immunomodulatory cells harboring OX40 ligand and 4-1BB ligand enhance antitumor immunity

Genetically modified tumor cells harboring immunomodulators may be used as therapeutic vaccines to stimulate antitumor immunity. The therapeutic benefit of these tumor vaccines is extensively investigated and mechanisms by which they boost antitumor response may be further explored. Tumor cells are...

Descripción completa

Detalles Bibliográficos
Autores principales: Semionatto, Isadora Ferraz, Palameta, Soledad, Toscaro, Jéssica Marcelino, Manrique-Rincón, Andrea Johanna, Ruas, Luciana Pereira, Paes Leme, Adriana Franco, Bajgelman, Marcio Chaim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495001/
https://www.ncbi.nlm.nih.gov/pubmed/32939048
http://dx.doi.org/10.1038/s41598-020-72122-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7495001/
https://www.ncbi.nlm.nih.gov/pubmed/32939048
http://dx.doi.org/10.1038/s41598-020-72122-3

Ejemplares similares